Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI StudyPau Montesinos, Jorge Labrador, Mar Tormo et al.|Journal of Clinical Oncology|2025Cited by 13
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA GroupsSusana Vives, Pau Montesinos, David Quintela et al.|Cancers|2024Cited by 4
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registryAna Alfonso Piérola, David Martínez‐Cuadrón, Rebeca Rodríguez‐Veiga et al.|Leukemia|2025Cited by 1
Erratum: Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI StudyPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|Journal of Clinical Oncology|2025Cited by 1